KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Cost of Revenue: 2014-2025

Historic Cost of Revenue for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $1.6 million.

  • Travere Therapeutics' Cost of Revenue fell 2.52% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 5.98%. This contributed to the annual value of $7.7 million for FY2024, which is 32.37% down from last year.
  • Travere Therapeutics' Cost of Revenue amounted to $1.6 million in Q3 2025, which was up 4.21% from $1.5 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Cost of Revenue high stood at $4.7 million for Q1 2025, and its period low was -$1.1 million during Q4 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $1.6 million (2024), whereas its average is $2.5 million.
  • Per our database at Business Quant, Travere Therapeutics' Cost of Revenue crashed by 151.64% in 2021 and then soared by 425.81% in 2023.
  • Travere Therapeutics' Cost of Revenue (Quarterly) stood at -$1.1 million in 2021, then soared by 181.12% to $868,000 in 2022, then skyrocketed by 425.81% to $4.6 million in 2023, then tumbled by 44.06% to $2.6 million in 2024, then decreased by 2.52% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.5 million for Q2 2025, and $4.7 million during Q1 2025.